Education
About Us
Working with TipRanks
Follow Us
Bristol-Myers Squibb (BMY)
NYSE:BMY
BMY Stock Chart & Stats
Day’s Range― - ―
52-Week Range$39.35 - $63.33
Previous CloseN/A
Volume3.98M
Average Volume (3M)12.58M
Market Cap
$123.93B
Enterprise Value$155.61B
Total Cash (Recent Filing)$10.35B
Total Debt (Recent Filing)$51.20B
Price to Earnings (P/E)―
Beta0.12
Next Earnings
Apr 24, 2025EPS Estimate
1.52Next Dividend Ex-Date
Apr 04, 2025Dividend Yield3.96%
Share Statistics
EPS (TTM)-4.43
Shares Outstanding2,029,312,000
10 Day Avg. Volume13,263,189
30 Day Avg. Volume12,575,243
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)2.57
Price to Cash Flow (P/CF)7.00
P/FCF Ratio7.60
Enterprise Value/Market Cap1.26
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit4.28
Enterprise Value/Ebitda49.31
Forecast
1Y Price Target
$61.00Price Target Upside-0.08% Downside
Rating ConsensusModerate Buy
Number of Analyst Covering15
---
Bulls Say, Bears Say
Bulls Say
AcquisitionBMY will acquire all outstanding shares of 2seventy bio, potentially saving future profit-sharing costs.
Drug ApprovalInvestors remain most focused on the commercial launch of Cobenfy, which received FDA approval.
Growth BusinessMomentum is building for the company's growth business with a strong launch from Cobenfy and outperformance from Camzyos, Reblozyl, and Breyanzi.
Bears Say
Clinical Trial SetbackOpdualag for the adjuvant treatment of patients with resected stage III-IV melanoma did not meet its primary endpoint of recurrence-free survival.
CompetitionIncreased pressure on Revlimid due to deteriorating Medicare access and a rise in generic competition could impact financial performance.
Legacy Business ChallengesThere are challenges for Bristol's legacy business, including the continued erosion of Revlimid and impacts from Part D reform.
---
Ownership Overview
0.05% Insiders
21.63% Mutual Funds
16.24% Other Institutional Investors
37.81% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
Finance & CorporateFinancial and accounting risks. Risks related to the execution of corporate activity and strategy
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
BMY FAQ
What was Bristol-Myers Squibb’s price range in the past 12 months?
Bristol-Myers Squibb lowest stock price was $39.35 and its highest was $63.33 in the past 12 months.
What is Bristol-Myers Squibb’s market cap?
Bristol-Myers Squibb’s market cap is $123.93B.
When is Bristol-Myers Squibb’s upcoming earnings report date?
Bristol-Myers Squibb’s upcoming earnings report date is Apr 24, 2025 which is in 29 days.
How were Bristol-Myers Squibb’s earnings last quarter?
Bristol-Myers Squibb released its earnings results on Feb 06, 2025. The company reported $1.67 earnings per share for the quarter, beating the consensus estimate of $1.463 by $0.207.
Is Bristol-Myers Squibb overvalued?
According to Wall Street analysts Bristol-Myers Squibb’s price is currently Overvalued.
Does Bristol-Myers Squibb pay dividends?
Bristol-Myers Squibb pays a Quarterly dividend of $0.62 which represents an annual dividend yield of 3.96%. See more information on Bristol-Myers Squibb dividends here
What is Bristol-Myers Squibb’s EPS estimate?
Bristol-Myers Squibb’s EPS estimate is 1.52.
How many shares outstanding does Bristol-Myers Squibb have?
Bristol-Myers Squibb has 2,029,312,000 shares outstanding.
What happened to Bristol-Myers Squibb’s price movement after its last earnings report?
Bristol-Myers Squibb reported an EPS of $1.67 in its last earnings report, beating expectations of $1.463. Following the earnings report the stock price went down -3.835%.
Which hedge fund is a major shareholder of Bristol-Myers Squibb?
Currently, no hedge funds are holding shares in BMY
---
Bristol-Myers Squibb Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$61.00 (-0.08% Downside)
$61.00 (-0.08% Downside)
Blogger Sentiment
Bullish
BMY Sentiment 95%
Sector Average 69%
Sector Average 69%
Hedge Fund Trend
Increased
By 4.7M Shares
Last Quarter.
Last Quarter.
Insider Transactions
Bought Shares
Worth $210.1K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Negative
Last 7 Days ▲ 0.1%
Last 30 Days ▼ 3.1%
Last 30 Days ▼ 3.1%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
23.43%
12-Months-Change
Fundamentals
Return on Equity
-39.10%
Trailing 12-Months
Asset Growth
-2.69%
Trailing 12-Months
Company Description
Bristol-Myers Squibb
Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, and markets biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, neuroscience, and covid-19 diseases. The company's products include Revlimid, an oral immunomodulatory drug for the treatment of multiple myeloma; Eliquis, an oral inhibitor for reduction in risk of stroke/systemic embolism in NVAF, and for the treatment of DVT/PE; Opdivo for anti-cancer indications; Pomalyst/Imnovid indicated for patients with multiple myeloma; and Orencia for adult patients with active RA and psoriatic arthritis. It also provides Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia; Yervoy for the treatment of patients with unresectable or metastatic melanoma; Abraxane, a protein-bound chemotherapy product; Reblozyl for the treatment of anemia in adult patients with beta thalassemia; and Empliciti for the treatment of multiple myeloma. In addition, the company offers Zeposia to treat relapsing forms of multiple sclerosis; Breyanzi, a CD19-directed genetically modified autologous T cell immunotherapy for the treatment of adult patients with relapsed or refractory large B-cell lymphoma; Inrebic, an oral kinase inhibitor indicated for the treatment of adult patients with myelofibrosis; and Onureg for the treatment of adult patients with AML. It sells products to wholesalers, distributors, pharmacies, retailers, hospitals, clinics, and government agencies. The company was formerly known as Bristol-Myers Company. The company was founded in 1887 and is headquartered in New York, New York.
---
BMY Company Deck
---
BMY Earnings Call
Q4 2025
0:00 / 0:00
Earnings Call Sentiment|Positive
The earnings call reflects a generally positive sentiment with strong growth in the company's key growth portfolio and significant achievements in commercial and R&D milestones. However, challenges remain in the legacy portfolio and impacts from Medicare Part D redesign. The company's strategic focus on operational excellence and financial discipline, along with accelerated R&D productivity, supports a positive outlook.Read More>---
BMY Revenue Breakdown
70.61% U.S.
27.33% International
2.06% Other
---
BMY Stock 12 Month Forecast
Average Price Target
$61.00
▼(-0.08% Downside)
Technical Analysis
Best Analysts Covering BMY
1 Year
1 Year Success Rate
14/20 ratings generated profit
1 Year Average Return
+2.60%
reiterated a buy rating 16 days ago
Copying David Risinger's trades and holding each position for 1 Year would result in 70.00% of your transactions generating a profit, with an average return of +2.60% per trade.
---